Tag: pharmaceuticals

  • European Approval Given for Cancer Pain Drug

    BioDelivery Sciences International (BDSI), a drug delivery technology company in Raleigh, North Carolina, said today its drug BREAKYL received approval for marketing by the German review authorities. Meda, a Swedish pharmaceutical company, partnered with BDSI on the development of the drug. The approval of BREAKYL by Germany will apply to all Europe Commission countries, since…

  • FDA Approves Anti-Coagulant Drug

    The German pharmaceutical company Boehringer Ingelheim said the U.S. Food and Drug Administration (FDA) approved its drug Pradaxa (dabigatran etexilate), an oral-administered direct thrombin inhibitor to reduce the risk of stroke in patients with non-valvular atrial fibrillation (AF).  The company says this is the first such approval of a new oral anti-coagulant in the U.S.…

  • Analytical Service Partners with Cancer Drug Makers

    Predictive Biomarker Sciences (PBS-Bio) in Mesa, Arizona said today that it signed new contracts with three companies developing therapies against a variety of cancers. PBS-Bio’s analysis helps pharmaceutical companies better understand how their drugs work, and identifies biomarkers that can help predict which patients will respond to treatment. The company’s three new pharmaceutical partners include:…

  • Max Planck Institute, GSK to Collaborate on Diabetes Drugs

    The Max Planck Institute of Biochemistry (MPI) in Martinsried, Germany and the German subsidiary of pharmaceutical company GlaxoSmithKline (GSK) have agreed on a partnership to develop new drugs for the treatment of type 2 diabetes. Max Planck Innovation, MPI’s technology transfer organisation, says the agreement is worth several million euros and covers a three-year period.…

  • Indian Biotech Develops Cell-Culture H1N1 Vaccine

    Bharat Biotech in Hyderabad, India said today it developed India’s first cell-culture H1N1 swine flu vaccine. The company believes it is the only developing world flu vaccine to be manufactured in cell culture, a faster and more advanced manufacturing process, instead of eggs. Traditional egg-based flu vaccine production requires long lead times — four to…

  • Sanofi-aventis, Harvard to Collaborate on Biomedical Research

    Sanofi-aventis, a global pharmaceutical company headquartered in Paris, and Harvard University in Cambridge, Massachusetts said today they established a collaboration to conduct basic and applied research in human health and promote scientific exchange between their organizations. The collaboration will focus on translational biomedical research in therapies for conditions such as cancer, diabetes and inflammation. Under…

  • Analysis of Patient Records Shows Results of H5N1 Flu Drug

    An analysis of clinical records stored in a registry of patients from various countries who contracted the influenza A/H5N1 (Avian flu) virus, shows that treatment with the drug oseltamivir reduces mortality in patients with the disease, even when given late in the course of illness. The findings were published in the Journal of Infectious Diseases.…

  • FDA Approves Subcutaneous Delivery of Immunodeficiency Drug

    Talecris Biotherapeutics, a biotechnology company in Research Triangle Park, North Carolina said today that the U.S. Food and Drug Administration (FDA) approved its Gamunex-C drug for subcutaneous administration in the treatment of primary immunodeficiency (PI). Subcutaneous administration — illustrated right — delivers the product under the skin into the subcutaneous tissue and intravenous administration is…

  • Grant Funds Company Clinical Trial of Addiction Drug

    Omeros Corporation, a biopharmaceutical company  in Seattle, Washington, said today that the National Institute on Drug Abuse (NIDA), part of National Institutes of Health, has provided an additional grant to fund clinical studies for the company’s addiction program. The grant will fund a clinical trial of the company’s drug on addiction to heroin and cigarettes.…

  • BARDA Awards Contract for Smallpox Antiviral Drug

    SIGA Technologies Inc. in New York, New York said today it received notice that the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), intends to award a contract for the company’s smallpox antiviral for the strategic national stockpile. SIGA says a protest from another company…